β-Blockers: A Review of Their Pharmacological and Physiological Diversity in Hypertension

Annals of Pharmacotherapy

Volumn 48, Issue 6, 2014, Pages 723-733

  Ripley, Toni L ^a   Saseen, Joseph J ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

central aortic pressure; hypertension; metabolic; pharmacodynamics; pharmacology; blockers

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; INSULIN; LIPID; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NEBIVOLOL; PLACEBO; PROPRANOLOL; BENZOPYRAN DERIVATIVE; CARBAZOLE DERIVATIVE; ETHANOLAMINE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

AORTA PRESSURE; BLOOD PRESSURE MEASUREMENT; CENTRAL AORTIC PRESSURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LIPID SOLUBILITY; MEDICAL LITERATURE; MEDLINE; METABOLIC PARAMETERS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; BLOOD PRESSURE; DRUG EFFECTS; METABOLISM;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BENZOPYRANS; BLOOD PRESSURE; CARBAZOLES; ETHANOLAMINES; HUMANS; HYPERTENSION; METOPROLOL; PROPANOLAMINES;

EID: 84899712664     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013519591     Document Type: Review

References (68)

1. Messerli FH,Beevers DG,Franklin SS,Pickering TG.Beta-blockers in hypertension-the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension.Am J Hypertens. 2003;16:870-873.
2. A cooperative study.JAMA. 1977;237:255-261.
3. Nelson CR,Knapp DA.Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians.Hypertension. 2000;36:600-603.
4. ChobanianAVBakrisGLBlackHR. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14656957.
5. Rosendorff C,Black HR,Cannon CP,et al.Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention.Circulation. 2007;115:2761-2788.
6. National Institute for Health and Clinical Excellence (NICE) Clinical Guideline. Hypertension: clinical management of primary hypertension in adults. http://www.nice.org.uk. Accessed on May 9, 2013.
7. Hackam DG,Quinn RR,Ravani P,et al.The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.Can J Cardiol. 2013;29:528-542.
8. Dahlof B,Devereux RB,Kjeldsen SE,et al.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.Lancet. 2002;359:995-1003.
9. Dahlof B,Sever PS,Poulter NR,et al.Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.Lancet. 2005;366:895-906.
10. Carlberg B,Samuelsson O,Lindholm LH.Atenolol in hypertension: is it a wise choice?.Lancet. 2004;364:1684-1689.
11. Lindholm LH,Carlberg B,Samuelsson O.Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis.Lancet. 2005;366:1545-1553.
12. Bradley HA,Wiysonge CS,Volmink JA,Mayosi BM,Opie LH.How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis.J Hypertens. 2006;24:2131-2141.
13. Khan N,McAlister FA.Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis.CMAJ. 2006;174:1737-1742.
14. Wiysonge CS,Bradley HA,Volmink J,et al.Beta-blockers for hypertension.Cochrane Database Syst Rev. 2012; (11): CD002003.
15. Warmack TS,Estes MA,Heldenbrand S,Franks AM.Beta-adrenergic antagonists in hypertension: a review of the evidence.Ann Pharmacother. 2009;43:2031-2043.
16. Elliott WJ,Childers WK.Should beta blockers no longer be considered first-line therapy for the treatment of essential hypertension without comorbidities?.Curr Cardiol Rep. 2011;13:507-516.
17. Top 200 Drugs for 2010 by units sold. http://www.drugs.com/top200_units.html. Accessed May 10, 2013.
18. Frishman WH,Saunders E.Beta-adrenergic blockers.J Clin Hypertens (Greenwich). 2011;13:649-653.
19. Kaplan NMKaplan's Clinical Hypertension. 9th ed.Philadelphia, PA: Lipincott Williams & Wilkins; 2006:1-518.Philadelphia, PA: Lipincott Williams & Wilkins; 2006:1-518.
20. Wilmington, DE: AstraZeneca; 2012:.
21. Pomona, NY: Duramed Pharmaceuticals; 2010:.
22. Research Triangle Park, NC: GlaxoSmithKline; 2011:.
23. Toprol XLWilmington, DE: AstraZeneca; 2012:.
24. Parsippany, NJ: Validus Pharmaceuticals; 2013:.
25. St Louis, MO: Forest Pharmaceuticals; 2010:.
26. Yue TL,Cheng HY,Lysko PG,et al.Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger.J Pharmacol Exp Ther. 1992;263:92-98.
27. Broeders MA,Doevendans PA,Bekkers BC,et al.Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production.Circulation. 2000;102:677-684.
28. Drayer DE.Lipophilicity, hydrophilicity, and the central nervous system side effects of beta blockers.Pharmacotherapy. 1987;7:87-91.
29. BenowitzNL. Antihypertensive agents. In: KatzungBGMastersSBTrevorAJ eds. Basic and Clinical Pharmacology. 12th ed.New York, NY: McGraw-Hill; 2012:chap 11. http://www.accesspharmacy.com/content.aspx?aID=55821618. Accessed September 18, 2013.
30. WestfallTCWestfallDP. Adrenergic agonists and antagonists. In: BruntonLLChabnerBAKnollmannBC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed.New York, NY: McGraw-Hill; 2011:chap 12. http://www.accesspharmacy.com/content.aspx?aID=16661344. Accessed September 18, 2013.
31. Cruickshank JM.The beta 1 hyperselectivity in beta-blocker treatment.J Cardiovasc Pharmacol. 1995;25:S35-S46.
32. van Brummelen P.The relevance of intrinsic sympathomimetic activity for beta-blocker-induced changes in plasma lipids.J Cardiovasc Pharmacol. 1983;5:S51-S55.
33. Vyssoulis GP,Karpanou EA,Pitsavos CE,et al.Differentiation of beta-blocker effects on serum lipids and apolipoproteins in hypertensive patients with normolipidaemic or dyslipidaemic profiles.Eur Heart J. 1992;13:1506-1513.
34. Packer M,Bristow MR,Cohn JN,et al.The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.N Engl J Med. 1996;334:1349-1355.
35. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).Lancet. 1999;353:2001-2007.
36. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.Lancet. 1999;353:9-13.
37. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.N Engl J Med. 2001;344:1659-1667.
38. Waagstein F,Bristow MR,Swedberg K,et al.Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group.Lancet. 1993;342:1441-1446.
39. Brodde OE,Bruck H,Leineweber K,Seyfarth T.Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart.Basic Res Cardiol. 2001;96:528-538.
40. Poole-Wilson PA,Cleland JG,Di Lenarda A,et al.Rationale and design of the Carvedilol or Metoprolol European trial in patients with chronic heart failure: COMET.Eur J Heart Fail. 2002;4:321-329.
41. Poole-Wilson PA,Swedberg K,Cleland JG,et al.Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.Lancet. 2003;362:7-13.
42. Williams B,Lacy PS,Thom SM,et al.Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.Circulation. 2006;113:1213-1225.
43. Roman MJ,Devereux RB,Kizer JR,et al.Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study.Hypertension. 2007;50:197-203.
44. Wang KL,Cheng HM,Chuang SY,et al.Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality?.J Hypertens. 2009;27:461-467.
45. Safar ME.Systolic hypertension in the elderly: arterial wall mechanical properties and the renin-angiotensin-aldosterone system.J Hypertens. 2005;23:673-681.
46. Wojciechowska W,Stolarz-Skrzypek K,Tikhonoff V,et al.Age dependency of central and peripheral systolic blood pressures: cross-sectional and longitudinal observations in European populations.Blood Press. 2012;21:58-68.
47. Morgan T,Lauri J,Bertram D,Anderson A.Effect of different antihypertensive drug classes on central aortic pressure.Am J Hypertens. 2004;17:118-123.
48. Mackenzie IS,McEniery CM,Dhakam Z,et al.Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension.Hypertension. 2009;54:409-413.
49. Vitale C,Marazzi G,Iellamo F,et al.Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study.Int J Cardiol. 2012;155:279-284.
50. Izzo JL,Rajpal M,Karan S,Srikakarlapudi S,Osmond PJ.Hemodynamic and central blood pressure differences between carvedilol and valsartan added to lisinopril at rest and during exercise stress.J Am Soc Hypertens. 2012;6:117-123.
51. Shah NK,Smith SM,Nichols WW,et al.Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study).J Clin Hypertens (Greenwich). 2011;13:917-924.
52. Kampus P,Serg M,Kals J,et al.Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness.Hypertension. 2011;57:1122-1128.
53. Polónia J,Barbosa L,Silva JA,Bertoquini S.Different patterns of peripheral versus central blood pressure in hypertensive patients treated with beta-blockers either with or without vasodilator properties or with angiotensin receptor blockers.Blood Press Monit. 2010;15:235-239.
54. Bangalore S,Parkar S,Grossman E,Messerli FH.A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus.Am J Cardiol. 2007;100:1254-1262.
55. Elliott WJ,Meyer PM.Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.Lancet. 2007;369:201-207.
56. Deedwania P.Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating beta-blockers.J Clin Hypertens (Greenwich). 2011;13:52-59.
57. Nonogaki K.New insights into sympathetic regulation of glucose and fat metabolism.Diabetologia. 2000;43:533-549.
58. Jacob S,Rett K,Henriksen EJ.Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents?.Am J Hypertens. 1998;11:1258-1265.
59. Sharma AM,Pischon T,Hardt S,Kunz I,Luft FC.Hypothesis: beta-adrenergic receptor blockers and weight gain. A systematic analysis.Hypertension. 2001;37:250-254.
60. Agabiti-Rosei E,Porteri E,Rizzoni D.Arterial stiffness, hypertension, and rational use of nebivolol.Vasc Health Risk Manag. 2009;5:353-360.
61. Jacob S,Rett K,Wicklmayr M,et al.Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study.J Hypertens. 1996;14:489-494.
62. Giugliano D,Acampora R,Marfella R,et al.Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial.Ann Intern Med. 1997;126:955-959.
63. Bakris GL,Fonseca V,Katholi RE,et al.Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.JAMA. 2004;292:2227-2236.
64. Torp-Pedersen C,Metra M,Charlesworth A,et al.Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol or Metoprolol European Trial (COMET).Heart. 2007;93:968-973.
65. Fogari R,Zoppi A,Lazzari P,et al.Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes.J Hum Hypertens. 1997;11:753-757.
66. Pesant Y,Marc-Aurele J,Bielmann P,et al.Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension.Am J Ther. 1999;6:137-147.
67. Poirier L,Cleroux J,Nadeau A,Lacourciere Y.Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients.J Hypertens. 2001;19:1429-1435.
68. Rizos E,Bairaktari E,Kostoula A,et al.The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study.J Cardiovasc Pharmacol Ther. 2003;8:127-134.